United Therapeutics Stock Forecast

Stock Price Forecast

The 12 analysts with 12-month price forecasts for United Therapeutics stock have an average target of 388.25, with a low estimate of 280 and a high estimate of 600. The average target predicts an increase of 22.36% from the current stock price of 317.29.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$280	$388.25	$400	$600
Change	-11.75%	+22.36%	+26.07%	+89.10%

Analyst Ratings

The average analyst rating for United Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	6	6	6	6	6	6
Buy	6	6	6	5	3	3
Hold	2	2	2	2	2	2
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	15	15	15	14	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Fein HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $425	Strong Buy	Reiterates	$425	+33.95%	Feb 27, 2025
Ashwani Verma UBS	UBS	Strong Buy Maintains $415 → $475	Strong Buy	Maintains	$415 → $475	+49.71%	Jan 8, 2025
Chris Shibutani Goldman Sachs	Goldman Sachs	Hold Maintains $243 → $302	Hold	Maintains	$243 → $302	-4.82%	Nov 1, 2024
Matthew Kaplan Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Maintains $319 → $344	Strong Buy	Maintains	$319 → $344	+8.42%	Oct 31, 2024
Hartaj Singh Oppenheimer	Oppenheimer	Buy Maintains $575 → $600	Buy	Maintains	$575 → $600	+89.10%	Oct 31, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

3.21B

from 2.88B

11.70%

from 2.88B

Revenue Next Year

3.42B

from 3.21B

6.50%

from 3.21B

EPS This Year

28.25

from 24.64

14.64%

from 24.64

EPS Next Year

29.80

from 28.25

5.50%

from 28.25

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.48B	1.69B	1.94B	2.33B	2.88B	3.21B	3.42B	3.62B
Revenue Growth	2.38%	13.63%	14.88%	20.20%	23.63%	11.70%	6.50%	5.84%
EPS	11.54	10.06	15.00	19.81	24.64	28.25	29.80	32.07
EPS Growth	-	-12.82%	49.11%	32.07%	24.38%	14.64%	5.50%	7.60%
Forward PE	-	-	-	-	-	11.23	10.65	9.90
No. Analysts	-	-	-	-	-	17	14	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	3.5B	3.7B	4.6B
Avg	3.2B	3.4B	3.6B
Low	2.9B	2.9B	2.7B

Revenue Growth

Revenue Growth	2025	2026	2027
High	20.4%	16.4%	34.2%
Avg	11.7%	6.5%	5.8%
Low	-0.8%	-10.5%	-20.7%

EPS Forecast

EPS	2025	2026	2027
High	31.26	43.12	43.12
Avg	28.25	29.80	32.07
Low	22.34	16.65	22.07

EPS Growth

EPS Growth	2025	2026	2027
High	26.9%	52.7%	44.7%
Avg	14.6%	5.5%	7.6%
Low	-9.3%	-41.1%	-25.9%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.